Breast Implants and Cancer: Here’s what you need to know

TGA and an update on BIA-ALCL

The TGA recently convened a panel to assess the safety of textured implants and the risk of ALCL.

Australian Society of Plastic Surgeons Professor Mark Ashton explains in this video what implants are associated with a higher incidence of ALCL and what the current recommendations are by the TGA.

Key points:

1. Patient needs to be genetically predisposed
2. Contamination during insertion: a critical factor for ALCL is exposure by a particular bacteria to the implant during the surgical procedure
3. Textured implant: ALCL is not associated with smooth implants

*Not all textured implants – Allergan and Polyeurethane have a risk of 1:2300. Between 5%-20% of all implants inserted are this kind of implant.

• Textured implants provide a legitimate role in breast surgery and their use should be considered on a case by case basis.
• Dr Tavakoli does not use Macro textured implants associated with the higher risk of ALC.
• Please see below for an extract from the TGA on BIA-ALCL

Q&A

What has the TGA been doing to monitor BIA-ALCL?

• The TGA has been monitoring BIA-ALCL since 2011 after receiving the first adverse event report in 2009. It established an expert working group in 2016 to seek advice on BIA-ALCL. The working group includes plastic surgeons, surgeons, breast-cancer surgeons, cancer epidemiologists, data analysts, public -health practitioners and consumers.
• The TGA has worked with this group to develop targeted information for consumers and health professionals.
• The introduction of a new requirement for Patient Information Leaflets for implantable devices commencing in 2018 enhances patient access to information.

Why hasn’t TGA immediately banned these products?

• There are a range of types of textured breast implants supplied in Australian. By compelling suppliers to provide additional information specific to the Australian market, the TGA can make well informed decisions about safety of particular types of implants. Suppliers have 10 working days to respond to the request for information. After receiving this information the TGA will consider action to suspend or cancel particular products.
• The decision by the French regulator appears to be based on events described to them from patients and doctors as well as data published about three implants, which has been extrapolated to other products. Other regulators, including those in the US, Germany and the UK are also seeking additional evidence on the risk of BIA-ALCL, and we are working closely with these regulators.
• Patients who have breast implants should expect that the regulator makes decisions based on sound scientific and medical evidence.
• Textured implants of varying roughness are used in 82% of operations in Australia. They play an important role in reconstructive surgery. Smooth implants are an alternative but they may require a higher rate of replacement reoperation due to greater rates of contracture of these implant.
• The international consensus is that there is no evidence supporting the removal of breast implants in the absence of properly diagnosed BIA-ALCL.

BIA-ALCL Breast Implants Australia: Understanding the Risks and What You Need to Know in 2025

Disclaimer: Any surgical or invasive procedure carries risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.

If you have breast implants or are considering breast augmentation, understanding the connection between breast implants and a rare form of lymphoma called BIA-ALCL is essential. This condition has raised important questions about breast implant safety across Australia and worldwide.

Breast Implant-Associated Anaplastic Large Cell Lymphoma affects a small number of women with textured breast implants. While the overall risk remains low, staying informed helps you make informed clinical choices about your health.

We’ll explore what current Australian data reveals about BIA-ALCL. You’ll learn about symptoms to monitor, the actions Australia’s Therapeutic Goods Administration has taken, and whether you should consider having your implants removed.

What Is BIA-ALCL? (Not Breast Cancer — Key Distinction)

BIA-ALCL stands for Breast Implant-Associated Anaplastic Large Cell Lymphoma. This is a type of non-Hodgkin’s lymphoma that can develop in the scar tissue and fluid surrounding breast implants.

Many women initially worry that BIA-ALCL is breast cancer. It is not. This rare form of lymphoma affects the immune system rather than breast tissue itself.

Anaplastic large cell lymphoma typically develops in the space between the breast implant and the capsule that forms around it. The capsule is scar tissue your body naturally creates around any implant.

Most cases of BIA-ALCL are diagnosed several years after implant placement. The average time from implantation to diagnosis ranges from eight to ten years. Some cases have been identified much sooner, while others appear after fifteen years or more.

When detected early, BIA-ALCL has high rates of clinical resolution. The majority of patients are successfully treated by removing the implant and the surrounding capsule. More advanced cases may require additional treatment, including chemotherapy or radiation.

Understanding this distinction between breast cancer and lymphoma helps reduce unnecessary anxiety. Both conditions are serious, but they develop differently and require different treatment approaches.

Key Distinction: BIA-ALCL is a lymphoma of the immune system, not breast cancer. It grows in the fluid and scar tissue around implants, not in breast tissue itself. Visit Breast Cancer Network Australia for more information about breast health.

BIA-ALCL Incidence Rates — What the Data Shows

Understanding your actual risk requires looking at reliable data from the Therapeutic Goods Administration and international research. The numbers provide important context for women with implants.

As of 2025, Australia has confirmed approximately 130 cases of BIA-ALCL since tracking began. The TGA continues to monitor and update these figures as new cases are reported.

Globally, researchers estimate the risk of developing BIA-ALCL ranges from one in 2,000 to one in 86,000 women with textured implants. The variation depends on implant type and surface texture characteristics.

Australian women with breast implants number in the hundreds of thousands. Given this large population, the confirmed case count remains relatively small. However, any risk deserves serious consideration when making decisions about your health.

The TGA has established a breast implant registry to improve tracking. This registry helps identify patterns and provides better risk assessment for different implant types.

Risk Factors That May Increase BIA-ALCL Likelihood

• Textured surface implants (macro-textured specifically)
• Longer duration of implant placement
• Certain implant brands with a higher surface texture
• Bacterial contamination during surgery

Factors That Do Not Increase Risk

• Smooth surface breast implants
• Saline versus silicone implant fill
• Breast augmentation versus reconstruction
• Geographic location within Australia

Most diagnosed cases involve specific textured implant brands. The Allergan Biocell textured implants represented a significant portion of BIA-ALCL cases before their suspension in Australia.

Which Implants Carry the Highest Risk?

Research consistently shows macro-textured breast implants carry a higher BIA-ALCL risk compared to smooth or micro-textured varieties. The degree of surface texturing appears directly related to lymphoma development.

Allergan Biocell implants demonstrated the strongest association with BIA-ALCL before their recall. These macro-textured implants had a distinctively rough surface pattern. Australian data showed elevated case numbers among women with this specific implant type.

Polyurethane-covered implants, popular in previous decades, also show an association with BIA-ALCL cases. These implants featured a foam coating that created tissue integration. While less common today, some Australian women still have these implants.

Other textured implant brands, including Mentor, Silimed, and Eurosilicone, have reported BIA-ALCL cases. However, the incidence rates vary significantly between manufacturers. For detailed information about implant types, read our guide on different types of breast implants.

The surface area and depth of texturing matter. Implants with deeper, more aggressive surface patterns show higher association rates with this rare lymphoma.

Implant Surface Type	BIA-ALCL Risk Level	Currently Available in Australia
Smooth Surface	Very Low to None	Yes
Micro-textured Surface	Low	Yes
Macro-textured (Biocell-type)	Higher	No (Suspended 2019)
Polyurethane-covered	Elevated	Limited Availability

TGA Action in Australia

The Therapeutic Goods Administration has taken decisive regulatory action to protect Australian women from breast implants with elevated BIA-ALCL risk. These measures reflect Australia’s commitment to patient safety and evidence-based medical regulation.

Australia’s response to BIA-ALCL concerns has been among the most proactive globally. The TGA implemented restrictions before many other countries took similar action. This early intervention has likely prevented additional cases among Australian women.

Allergan Biocell Suspension 2019

In July 2019, the TGA cancelled the registration of Allergan Biocell textured breast implants and tissue expanders. This action removed these macro-textured products from the Australian market immediately.

The decision followed mounting evidence linking Biocell implants to a disproportionate number of BIA-ALCL cases worldwide. Australian data showed similar patterns, prompting regulatory intervention.

Women who already had Biocell implants received guidance through the TGA and their surgeons. The suspension did not mandate removal for all patients. Instead, the TGA recommended individualised assessment and monitoring.

This recall represented one of the most significant breast implant regulatory actions in Australian history. The Allergan Biocell recall in Australia set a precedent for evidence-based implant regulation.

Allergan Australia issued patient information and established support resources. Surgeons contacted patients with Biocell implants to discuss their individual situations and monitoring plans.

The 2019 TGA action on Allergan Biocell implants was a suspension of product registration, not a mandatory recall requiring removal from all patients. Women with these implants should discuss their individual risk with a qualified plastic surgeon.

For more information about this topic, read our comprehensive article on breast implants and BIA-ALCL updates.

Symptoms to Watch For

Recognising potential BIA-ALCL symptoms enables early detection and treatment. Most women with this condition notice changes years after their initial breast implant surgery.

The most common presentation involves late-onset swelling in one breast. This swelling typically occurs at least one year after implant placement, often many years later. Sudden breast enlargement without injury or obvious cause warrants medical evaluation.

Fluid accumulation around the implant creates this swelling. The fluid collection is called a seroma. While seromas can occur for various reasons, persistent or late-developing fluid accumulation requires investigation.

Some women notice a lump in the breast or armpit area. These lumps form when lymphoma cells create a mass within the capsule or nearby tissue. Any new breast lump demands prompt medical assessment regardless of implant status.

Primary BIA-ALCL Warning Signs

• Swelling in one breast occurring years after implant placement
• Persistent fluid accumulation around the implant
• A new lump in the breast tissue or capsule
• Asymmetric breast enlargement without explanation
• Firmness or hardening around the implant
• Pain or discomfort in the affected breast

When to Seek Urgent Evaluation

• Sudden breast swelling more than one year post-surgery
• Any palpable lump in the breast or armpit
• Persistent pain or unusual sensations
• Visible changes in breast shape or size
• Skin changes over the implant area
• Unexplained breast firmness or capsular contracture

Pain in the affected breast can accompany swelling. However, BIA-ALCL often develops without significant pain. Some women report only mild discomfort or pressure sensations.

Changes in breast shape or contour may become noticeable. The affected breast might appear fuller or more projected than before. Asymmetry between breasts that develops gradually also warrants attention.

Skin changes over the implant rarely occur but can indicate advanced disease. Redness, dimpling, or unusual texture deserve immediate evaluation.

Important: These symptoms can indicate various conditions, not only BIA-ALCL. Capsular contracture, implant rupture, infection, and other complications cause similar presentations. Any concerning changes require professional assessment to determine the cause. Learn more about capsular contracture and treatment options.

Women with breast implants should perform regular self-examinations. Familiarity with your normal breast appearance and feel helps you notice changes early. Report any concerns to your surgeon promptly.

Experiencing Any of These Symptoms?

If you notice breast swelling, lumps, or unusual changes with your implants, schedule an urgent safety assessment. Dr Tavakoli, FRACS(Plast), provides comprehensive evaluations for women with breast implant concerns. Early detection ensures the best outcomes for any implant-related condition.

Call Now: 1300 368 107

Book Consultation

Diagnosis and Treatment

• Clinical Assessment: Physical examination and medical history review to document symptoms and timeline
• Imaging Studies: Ultrasound and possibly MRI to visualise fluid collections or masses
• Fluid Aspiration: Fine needle aspiration to collect fluid samples from around the implant
• Pathological Analysis: Laboratory testing of fluid or tissue for BIA-ALCL cell markers
• Staging Workup: Additional tests if BIA-ALCL is confirmed to determine disease extent
• Treatment Planning: Multidisciplinary team consultation to determine optimal treatment approach

Complete Removal Benefits

• High cure rate for early-stage disease
• Removes the source of ongoing inflammation
• Eliminates future BIA-ALCL risk from that implant
• Provides definitive tissue diagnosis
• Allows reconstruction with safer alternatives

Treatment Considerations

• Surgery carries standard operative risks
• Recovery time needed after capsulectomy
• Breast appearance changes after removal
• Replacement timing must be carefully planned
• Advanced cases may need additional therapy

Women diagnosed with BIA-ALCL often experience anxiety and uncertainty. Support from experienced surgeons and oncology teams helps navigate this challenging diagnosis. Most patients achieve excellent outcomes with appropriate treatment.

Should You Have Your Implants Removed?

This question concerns many women with breast implants, especially those with textured varieties. The decision requires careful consideration of your individual circumstances and implant type.

The TGA does not recommend routine removal of all breast implants due to BIA-ALCL concerns. Most women with implants will never develop this condition. Prophylactic removal for asymptomatic women remains a personal choice rather than a medical mandate.

Women with confirmed Allergan Biocell implants face a more complex decision. These macro-textured implants carry a higher BIA-ALCL risk than other varieties. However, the absolute risk remains low even for this implant type.

Your surgeon can help assess your individual risk factors. These include implant type, duration of implantation, presence of symptoms, and personal anxiety levels about the risk.

Some women choose removal for peace of mind despite low absolute risk. This is a valid personal decision when other factors like implant age or desired aesthetic changes also exist.

Consider Removal If You Have:

• Any symptoms suggesting BIA-ALCL
• Confirmed Allergan Biocell macro-textured implants
• Significant anxiety affecting quality of life
• Other reasons for revision surgery
• Aged implants needing replacement anyway
• Personal preference for removal despite low risk

Removal May Not Be Urgent If You Have:

• Smooth surface implants with no symptoms
• Micro-textured implants are functioning well
• No personal risk factors or concerns
• Recent implant placement (within 5 years)
• Good health and regular monitoring
• Comfort with your current implants

Financial considerations matter for some patients. Elective removal without medical necessity may not receive insurance coverage. Discuss costs and coverage with your surgeon’s office before making decisions.

If you proceed with removal, consider whether you want replacement implants. Smooth implants offer continued augmentation with minimal BIA-ALCL risk. Alternatively, removal without replacement or fat grafting reconstruction are options.

Complete capsulectomy at the time of removal provides the most thorough approach. Removing all capsule tissue eliminates any theoretical future risk from chronic inflammation. For comprehensive information about the removal process, visit our breast implant removal guide.

Recovery from explantation surgery varies by technique. Simple removal recovers faster than removal with capsulectomy. Simultaneous replacement extends recovery somewhat compared to removal alone.

Personalised Assessment: The decision to remove breast implants should be individualised based on your implant type, symptoms, risk factors, and personal preferences. Consultation with an experienced plastic surgeon provides the information you need to make an informed clinical choice.

Frequently Asked Questions About BIA-ALCL

How common is BIA-ALCL in Australia?

BIA-ALCL remains rare in Australia, with approximately 130 confirmed cases since tracking began. Given the hundreds of thousands of Australian women with breast implants, your individual risk is low. However, the condition does occur, making awareness important for all women with textured implants.

Can BIA-ALCL develop with smooth implants?

The vast majority of BIA-ALCL cases involve textured implants, particularly macro-textured varieties. Very few cases have been documented with smooth implants globally. The TGA and international research indicate smooth implants carry minimal to no BIA-ALCL risk. Women with smooth implants can feel reassured about this specific concern.

What should I do if I have Allergan Biocell implants?

Women with Allergan Biocell implants should remain vigilant for symptoms, but do not need immediate removal unless symptoms develop. Schedule regular monitoring with your plastic surgeon. Discuss your individual risk factors and whether removal makes sense for your situation. Many women with these implants never develop problems, but informed decision-making is important.

How long after implant surgery can BIA-ALCL develop?

Most BIA-ALCL cases are diagnosed eight to ten years after implant placement. However, the condition can develop sooner or much later. Cases have been identified as early as two years and as late as twenty years post-implantation. This delayed presentation makes long-term awareness essential for all women with implants.

Is BIA-ALCL the same as breast cancer?

No. BIA-ALCL is a type of lymphoma affecting the immune system, not breast cancer. While both are serious conditions, they develop in different cell types and require different treatments. BIA-ALCL typically has high rates of clinical resolution when detected early, with most women cured by implant and capsule removal.

What tests diagnose BIA-ALCL?

Diagnosis begins with imaging studies like ultrasound or MRI to identify fluid collections or masses. Confirming BIA-ALCL requires fluid aspiration or tissue biopsy. Pathologists examine samples for characteristic cell markers, including CD30 positivity. Your surgeon will coordinate all necessary testing if BIA-ALCL is suspected.

Can BIA-ALCL be cured?

Yes. Early-stage BIA-ALCL has high rates of clinical resolution exceeding 90 per cent with complete surgical removal of the implant and surrounding capsule. Most women require no additional treatment beyond surgery. Advanced cases involving spread beyond the capsule may need chemotherapy or radiation, but these situations are uncommon with early detection.

Should I avoid breast implants completely due to BIA-ALCL risk?

This is a personal decision requiring consideration of benefits versus risks. Smooth breast implants carry minimal BIA-ALCLs. Micro-textured implants also show a lower risk than the discontinued macro-textured varieties. Many women proceed with breast augmentation after understanding current safety data and choosing appropriate implant types.

How often should I check my implants for problems?

Perform monthly self-examinations to become familiar with your normal breast appearance and feel. Schedule annual check-ups with your plastic surgeon for professional assessment. Seek immediate evaluation if you notice any concerning changes, including swelling, lumps, pain, or asymmetry. Regular monitoring enables early detection of any implant-related complications.

Does health insurance cover BIA-ALCL screening or treatment?

Coverage varies by insurance provider and policy details. Diagnostic testing for symptoms typically receives coverage as a medically necessary evaluation. Treatment for confirmed BIA-ALCL usually has coverage as cancer care. Prophylactic removal without symptoms may not receive coverage. Contact your insurance provider to understand your specific policy provisions.

Where can I find more information about breast implant safety?

The Therapeutic Goods Administration website provides official Australian guidance on breast implant safety. Your plastic surgeon can offer personalised information based on your specific implant type and situation. Organisations like Breast Cancer Network Australia also provide educational resources about breast health.

Your Breast Implant Safety Starts With Expert Guidance

Understanding BIA-ALCL and breast implant safety helps you make informed decisions about your health. While this rare lymphoma deserves awareness, most women with breast implants never experience this condition.

Current TGA regulations ensure that breast implants available in Australia meet rigorous safety standards. The suspension of high-risk macro-textured implants has significantly enhanced patient safety.

Women with existing implants should remain vigilant for symptoms while avoiding unnecessary anxiety. Regular monitoring and prompt attention to any changes provide the best protection through early detection.

Those considering breast augmentation have access to safe implant options with minimal BIA-ALCL risk. Smooth and micro-textured implants offer satisfactory anatomical outcomes without the elevated risk associated with discontinued macro-textured varieties.

Concerned About Your Breast Implants? Get Expert Assessment

Dr Tavakoli, FRACS(Plast), provides comprehensive breast implant safety reviews for Australian women concerned about BIA-ALCL or other implant-related issues. With extensive training and experience in breast surgery, Dr Tavakoli offers evidence-based guidance tailored to your individual situation.

Whether you need symptom evaluation, risk assessment, or guidance about implant options, our team delivers expert care with compassion and understanding. We stay current with the latest TGA guidelines and international research to provide you with accurate, trustworthy information.

Call for Safety Review: 1300 368 107

Book Your Consultation